Home/Pipeline/VIP943

VIP943

Hematologic Malignancies (e.g., AML)

Phase 1Active

Key Facts

Indication
Hematologic Malignancies (e.g., AML)
Phase
Phase 1
Status
Active
Company

About Vincerx Pharma

Vincerx Pharma is dedicated to accelerating the development of life-changing medicines for cancer patients with high unmet needs. The company employs a capital-efficient, virtual R&D model to advance a diverse pipeline of small molecules and biologics, including both proprietary and in-licensed assets. Its strategy focuses on strategic partnerships and targeted clinical development to maximize the potential of its oncology portfolio. Vincerx aims to address significant market opportunities in oncology through precision medicine approaches.

View full company profile

Therapeutic Areas

Other Hematologic Malignancies (e.g., AML) Drugs

DrugCompanyPhase
CD33 Shielding PlatformCimeio TherapeuticsPre-clinical